Foley Hoag Represents Organogenesis in Merger with Avista Healthcare Public Acquisition Corp.

August 17, 2018

Foley Hoag LLP represented Organogenesis Inc., a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care, Surgical and Sports Medicine markets, in a definitive merger agreement with Avista Healthcare Public Acquisition Corp. (NASDAQ: AHPA ) ("AHPAC"), a publicly traded special purpose acquisition company.

Affiliates of Avista Capital Partners, a leading private equity firm, have agreed to invest $92 million in the combined company in conjunction with the transaction.  Following the closing of the transaction, Organogenesis will be listed on the Nasdaq Stock Exchange under the ticker symbol “ORGO.”  The combined company will have an anticipated initial enterprise value of approximately $673 million.

Foley Hoag partners William Kolb and Stacie Aarestad and associates Ryan Rourke Reed, Remi Kathawa and Justin Beegle represented Organogenesis in the transaction.

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.